Ultime notizie per Exscientia (NASDAQ:EXAI) Azioni

Exscientia

Exscientia PLC is engaged in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of novel therapeutic compounds. The company's technology platform combines human and computational capabilities to accelerate the process of designing novel, safe, and efficacious compounds for clinical testing in humans. The company is focused on the discovery and development of small-molecule drug candidates.

Exscientia Plc - American Depositary Shares

Exscientia PLC

Exail Technologies SA

The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug Discovery Stocks Portfolio by 6.6% on the day. 

AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!

The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual sales in excess of $50B.

AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th

The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual sales in excess of $50B.

AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Exscientia Plc (EXAI – Research Report), with a price ta...

Morgan Stanley Sticks to Its Hold Rating for Exscientia Plc (EXAI)

Exscientia Plc (EXAI) Receives a Hold from Morgan Stanley

Morgan Stanley Remains a Hold on Exscientia Plc (EXAI)

Exscientia Plc (EXAI) has released an update. Exscientia plc has entered into a definitive agreement for acquisition by Recursion Pharmaceuticals, ...

Exscientia Set for Strategic Acquisition by Recursion

Recursion, Exscientia seek support for merger ahead of special meeting

Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Exscientia Plc (EXAI – Research Report) today and set a price target of $5.70. Th...

Morgan Stanley Reaffirms Their Hold Rating on Exscientia Plc (EXAI)

Exscientia to receive $15M in milestones for Sanofi collaboration

ABCL

ABSI

EXAI

NVDA

RLAY

RXRX

SDGR

Press Releases

Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout

Latest Updates of Viva Biotech's Portfolio Companies

General

Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates

Exscientia Business Update for Second Quarter and First Half 2024

Exscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Opinion

AI Revolution in Healthcare Gains Momentum as FDA Prepares for Tech Boom

Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting

Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024

Comments

Exscientia

Notizie

Ultime notizie per Exscientia (NASDAQ:EXAI) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO